DrugPatentWatch Database Preview

Larotrectinib - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for larotrectinib and what is the scope of larotrectinib patent protection?

Larotrectinib is the generic ingredient in one branded drug marketed by Bayer Hlthcare and Bayer Healthcare, and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Larotrectinib has one hundred and twenty-eight patent family members in forty countries.

One supplier is listed for this compound.

Summary for larotrectinib

International Patents:	128
US Patents:	10
Tradenames:	1
Applicants:	2
NDAs:	2
Suppliers / Packagers:	1
Bulk Api Vendors:	20
Clinical Trials:	2
Patent Applications:	30
DailyMed Link:	larotrectinib at DailyMed

Synonyms for larotrectinib

(3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide

(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide

(S)-N-(5 -((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin -1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3 yl)-3-hydroxypyrrolidine-1-carboxamide

(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-

1223403-58-4

AKOS027338709

ARRY 470

ARRY-470

ARRY470

ARRY470;ARRY-470;ARRY 470;LOXO 101;LOXO101;Larotrectinib

AS-35231

BCP16262

BDBM136597

CHEMBL3889654

CS-5722

D11137

EX-A1981

example 14 [US8865698 B2]

GTPL8909

HY-12866

J3.628.138C

Larotrectinib (USAN/INN)

Larotrectinib [USAN:INN]

LOXO 101

LOXO-101

LOXO101

NYNZQNWKBKUAII-KBXCAEBGSA-N

PF9462I9HX

SCHEMBL2241012

UNII-PF9462I9HX

US8865698, 14

ZINC118399834

US Patents and Regulatory Information for larotrectinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare	VITRAKVI	larotrectinib	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes
Bayer Healthcare	VITRAKVI	larotrectinib	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes
Bayer Hlthcare	VITRAKVI	larotrectinib	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes
Bayer Healthcare	VITRAKVI	larotrectinib	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes
Bayer Healthcare	VITRAKVI	larotrectinib	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes
Bayer Hlthcare	VITRAKVI	larotrectinib	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No

International Patents for larotrectinib

Country	Patent Number	Estimated Expiration
European Patent Office	2350071
World Intellectual Property Organization (WIPO)	2017176744
South Korea	20160104085
Lithuania	3106463
Israel	262003
Chile	2017001249